Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma
The Oncologist · 06.12.2024 · 29 (12) · 1003-1013
DOI: 10.1093/oncolo/oyae215 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Oncologist, online erschienen am 21.08.2024. Verfasst von Tian Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Platinum-based chemotherapy has been the standard first-line (1L) treatment for advanced urothelial carcinoma (UC) for decades, based on the proven efficacy and established safety profiles of cisplatin- and carboplatin-based regimens. With the emergence of novel regimens, it is important to reevaluate and contextualize the role of 1L platinum-based chemotherapy. Platinum-based chemotherapy followed by avelumab 1L maintenance in patients without disease progression following platinum-based chemotherapy was established as a standard 1L regimen based on the JAVELIN Bladder 100 phase III trial. More recently, the EV-302 phase III trial showed the superiority of 1L enfortumab vedotin (EV) + pembrolizumab versus platinum-based chemotherapy, and the Checkmate 901 phase III trial showed the superiority of 1L nivolumab + cisplatin/gemcitabine versus cisplatin/gemcitabine alone. These 2 regimens have now been included as standard 1L options in treatment guidelines for advanced UC. EV + pembrolizumab is now the preferred 1L treatment, and in locations where EV + pembrolizumab is not available or individual patients are not considered suitable, recommended options are platinum-based chemotherapy followed by avelumab maintenance or nivolumab + cisplatin-based chemotherapy. In this review, we discuss current treatment options for advanced UC recommended in guidelines, practical considerations with platinum-based chemotherapy, the role of avelumab 1L maintenance, recent phase III trials of EV + pembrolizumab and nivolumab + cisplatin/gemcitabine, safety profiles of recommended 1L treatments, and second-line treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States.
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
- Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
- EMD Serono, Inc., Rockland, MA, United States, an affiliate of Merck KGaA.
- Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Tian Zhang
Förderung
- NCI NIH HHS
Zitieren
APA
Zhang, T., Tan, A., Shah, A. Y., Iyer, G., Morris, V., Michaud, S., & Sridhar, S. S. (2024). Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma. The Oncologist, 29(12), 1003-1013. https://doi.org/10.1093/oncolo/oyae215
Vancouver
Zhang T, Tan A, Shah AY, Iyer G, Morris V, Michaud S, et al. Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma. The Oncologist. 2024;29(12):1003-1013. doi:10.1093/oncolo/oyae215
BibTeX
@article{Zhang2024,
author = {Zhang, Tian and Tan, Alan and Shah, Amishi Y and Iyer, Gopa and Morris, Valerie and Michaud, Sébastien and Sridhar, Srikala S},
title = {Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {12},
pages = {1003--1013},
doi = {10.1093/oncolo/oyae215}
}
EUVIMED